Bangalore, India: February 5, 2014
Syngene, India's leading contract research organization and Baxter International Inc., a leading global pharmaceutical company have collaborated to establish the Baxter Global Research Center at Syngene, in Bangalore.
The Center was inaugurated by Shri Ghulam Nabi Azad, the Honorable Minister of Health and Family Welfare, Govt. of India, in the presence of Shri U T Khader, Minister of Health & Family Welfare, Govt. of Karnataka, Shri S R Patil, Minister of IT, BT & ST, Govt. of Karnataka, Shri Keshav Desiraju, Secretary, Dept. of Health & Family Welfare, Govt. of India and Shri Srivatsa Krishna, Secretary, Dept. of IT, BT & ST, Govt. of Karnataka.
The Baxter Global Research Center (BGRC) at Syngene, is a part of Baxter’s global strategy of building R&D collaborations with strategic partners. This collaboration will support Baxter in the Research and Development of medical products and devices to serve patients both in India and around the world.
A team of over 100 multidisciplinary Syngene scientists will be based at this dedicated Center of Excellence at Syngene in Biocon Park, Bangalore. The Syngene team, working closely with Baxter scientists, will engage in a wide range of R&D activities centered on product and analytical development and pre-clinical evaluation in parenteral nutrition and renal therapy.
Speaking at the inauguration, Jean-Luc Butel, Corporate Vice President & President- International, Baxter, said, " Baxter is pleased to be part of the opening of this Syngene facility dedicated to providing Baxter with technical and scientific capabilities that will augment our own internal resources. Baxter is committed to helping save and sustain patients’ lives worldwide, and innovation is the driver of success in this area.”
Kiran Mazumdar Shaw, Chairperson, Biocon, said: "Biocon is pleased to partner with Baxter through its research services arm, Syngene. We share a common vision with Baxter, focused on developing pharmaceutical products that advance patient care worldwide and this new research center will be a significant step towards enabling that objective."
Commenting on the collaboration, Peter Bains, Director, Syngene International Limited, said, "We are proud and excited to be collaborating with Baxter in establishing the Baxter Global Research Center at Syngene in India. The scale and scope of activities signal the strategic nature of the collaboration and also reflect Syngene’s capabilities to offer broad based complimentary integrated development services. We look forward to working closely with Baxter’s scientists to support advancing their R&D goals.”
The rising incidence of chronic diseases like diabetes, cancer, cardiovascular and renal diseases pose an enormous challenge and disease burden for the various healthcare systems around the world. There is a compelling need to intensify R&D efforts for developing novel therapeutics and diagnostic capabilities that enable various governments meet the challenges of affordability and access to treatment. Syngene and Baxter’s collaboration is aimed at making a contribution to this greater cause.
About Syngene International Limited
Syngene, is a wholly owned subsidiary of Biocon Limited, Asia’s leading biotechnology company. It is well recognized as India's leading contract research organization offering integrated drug discovery and development services with capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process Research and Development, and formulation development for small and large molecules. The Company has an expert team of over 2,000 scientists and 1 million sq. ft. of built-up laboratories equipped with state-of-the-art infrastructure to support the Research and Development programs of global pharma, biotech and nutrition companies. More information is available at www.syngeneintl.com
About Baxter International Inc.
Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
For further information, please contact:
Media Relations
Seema Ahuja
Phone: +91 080 2808 2808
Email: seema.ahuja@biocon.com
Rumman Ahamed
Phone: +91 080 2808 2808
Email: rumman.ahmed@biocon.com
Investor Relations
Saurabh Paliwal
Phone: +91 95383 80801
Email: saurabh.paliwal@biocon.com
|
